EFFICACY OF CHECKPOINT INHIBITOR IMMUNOTHERAPY DRUG PEMBROLIZUMAB (KEYTRUDA) FOR TREATMENT OF ADVANCED CERVICAL CANCER

被引：0
|
作者：
Ahmed, F. [1 ]
Shah, Z. [2 ]
Khan, I. [1 ]
Bhatnagar, A. [1 ]
Garimella, R. [1 ]
Mishra, S. [1 ]
Gudapati, S. [3 ]
Bobba, S. H. [3 ]
Zaidi, S. [4 ]
Andrews, K. [5 ]
Salman, U. [6 ]
Yukselen, Z. [1 ]
Guntipalli, P. [1 ]
Zarrar, R. [7 ]
Nya, G. Enebong [8 ]
Ahmad, S. [9 ]
机构：
[1] Larkin Community Hosp, Div Clin & Translat Res, South Miami, FL USA
[2] Weiss Mem Hosp, Dept Internal Med, Chicago, IL USA
[3] Washington Univ Hlth & Sci, Coll Med, San Pedro, Belize
[4] Lahore Med & Dent Coll, Coll Med, Lahore, Pakistan
[5] Prince Mohammad Bin Fahad Univ, Dept CORE, Al Khobar, Saudi Arabia
[6] Bakhtawar Amin Med & Dent Coll, Coll Med, Multan, Pakistan
[7] Mayo Clin, Dept Oncol, Rochester, MN USA
[8] Johns Hopkins Univ Hosp, Dept Gynecol Oncol, Baltimore, MD USA
[9] Advent Hlth Canc Inst, Div Gynecol Oncol, Orlando, FL USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2021年 / 31卷
关键词：
D O I：
10.1136/ijgc-2021-ESGO.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
567
引用
收藏
页码：A32 / A32
页数：1
相关论文
共 50 条
  • [21] Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
    Rodriguez-Pascual, Jesus
    Ayuso-Sacido, Angel
    Belda-Iniesta, Cristobal
    CANCER DRUG RESISTANCE, 2019, 2 (04) : 980 - 993
  • [22] Response and re-treatment response to immune checkpoint inhibitor treatment in advanced cervical cancer: A follow up study
    Wolf, Jennifer
    Xu, Yiqing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
    Johns, Andrew C.
    Wei, Lai
    Grogan, Madison
    Hoyd, Rebecca
    Bridges, John F. P.
    Patel, Sandipkumar H.
    Li, Mingjia
    Husain, Marium
    Kendra, Kari L.
    Otterson, Gregory A.
    Burkart, Jarred T.
    Rosko, Ashley E.
    Andersen, Barbara L.
    Carbone, David P.
    Owen, Dwight H.
    Spakowicz, Daniel J.
    Presley, Carolyn J.
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 813 - 819
  • [24] Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy
    Butner, Joseph D.
    Elganainy, Dalia
    Wang, Charles X.
    Wang, Zhihui
    Chen, Shu-Hsia
    Esnaola, Nestor F.
    Pasqualini, Renata
    Arap, Wadih
    Hong, David S.
    Welsh, James
    Koay, Eugene J.
    Cristini, Vittorio
    SCIENCE ADVANCES, 2020, 6 (18):
  • [25] The efficacy and safety of pembrolizumab in advanced cervical cancer-A real world treatment study in an irish healthcare setting.
    Browne, Iseult
    Fennelly, David William
    Crown, John
    Murray, Hazel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Immunotherapy for advanced or relapsed cervical cancer
    Lin, Cheng-Tao
    Wang, Chao-Nin
    Lai, Chyong-Huey
    GYNECOLOGY AND MINIMALLY INVASIVE THERAPY-GMIT, 2013, 2 (01): : 3 - 7
  • [27] Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
    Muir, Christopher A.
    Menzies, Alexander M.
    Clifton-Bligh, Roderick
    Tsang, Venessa H. M.
    THYROID, 2020, 30 (10) : 1458 - 1469
  • [28] The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer
    Otter, S. J.
    Chatterjee, J.
    Stewart, A. J.
    Michael, A.
    CLINICAL ONCOLOGY, 2019, 31 (12) : 834 - 843
  • [29] Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer
    Antonarakis, Emmanuel S.
    ASIAN JOURNAL OF ANDROLOGY, 2012, 14 (04) : 520 - 521
  • [30] Breast Cancer, Cervical Cancer and Endometrial Cancer Immunotherapy with Pembrolizumab prolongs Life
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (05)
12345